This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB04884/identifier/wikipedia/
n13http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB04884/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB04884/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04884/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04884/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/sukl/drug/
n15http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04884/identifier/chemspider/

Statements

Subject Item
n2:DB04884
rdf:type
n3:Drug
n3:description
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.
n3:generalReferences
# Safarinejad MR: Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study. Neuropsychopharmacology. 2007 Jul 11;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17625501 # Cirillo-Penn K, Modi NB: Dapoxetine and Paroxetine for the Treatment of Premature Ejaculation. Clin Neuropharmacol. 2007 September/October;30(5):315. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17909314 # McMahon C: Dapoxetine in the treatment of premature ejaculation. Clin Neuropharmacol. 2007 Sep-Oct;30(5):314-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17909313 # Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007 Jun 5;120(11):1000-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17624269 # Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S: Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9;368(9539):929-37. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16962882 # Hellstrom WJ, Heintz JW: Treatment of premature ejaculation: new drugs and treatment strategies. Curr Urol Rep. 2006 Nov;7(6):473-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17052444 # Modi NB, Dresser M, Desai D, Edgar C, Wesnes K: Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol. 2007 Mar;47(3):315-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17322143 # Payne RE, Sadovsky R: Identifying and treating premature ejaculation: importance of the sexual history. Cleve Clin J Med. 2007 May;74 Suppl 3:S47-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17546831
n3:group
investigational
n3:halfLife
Initial half-life of 1-2 hours.
n3:indication
For the treatment of premature ejaculation.
owl:sameAs
n13:DB04884
dcterms:title
Dapoxetine
adms:identifier
n6:64453 n7:71353 n8:14849767 n9:DB04884 n10:D03649 n16:Dapoxetine
n3:mechanismOfAction
The drug's mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT's modulating activity on ejaculation.
n3:synonym
Dapoxetinum Dapoxetina
n3:IUPAC-Name
n4:271B5CDD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5CE3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5CE2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5CDF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5CE0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5CE1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5CDB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5CD9-363D-11E5-9242-09173F13E4C5 n4:271B5CDC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5CDA-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:G04BX14
n3:H-Bond-Acceptor-Count
n4:271B5CE9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5CEA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5CE4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5CE5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5CE7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5CE6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5CE8-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
119356-77-3
n3:category
n3:Bioavailability
n4:271B5CEE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5CF0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5CF1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5CED-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5CEC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5CEF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5CDE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5CEB-363D-11E5-9242-09173F13E4C5